Anthera Pharmaceuticals

company

About

Anthera Pharmaceuticals is focused on developing products to treat diseases associated with inflammation and autoimmune diseases.

  • 1 - 10

Details

Last Funding Type
Post-IPO Debt
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2004
Number Of Employee
1 - 10
Operating Status
Active

Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$55M
Anthera Pharmaceuticals has raised a total of $55M in funding over 2 rounds. Their latest funding was raised on Jan 1, 2011 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 1, 2011 Post-IPO Debt 1 Detail
Aug 14, 2008 Series Unknown $19M 1 Caxton Advantage Life Sciences Fund Detail
Sep 13, 2006 Series Unknown $36M 2 Detail

Investors

Number of Lead Investors
Number of Investors
1
4
Anthera Pharmaceuticals is funded by 4 investors. Caxton Advantage Life Sciences Fund and Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Caxton Advantage Life Sciences Fund Yes Series Unknown
Hercules Capital Post-IPO Debt
SIM Equity Series Unknown
Sears Capital Management Series Unknown